(CTXR) Update: Going Red To Green Moments Ago, This Nasdaq Past Champs Need Full Focus
CTXR requires immediate attention this morning.
With the overall markets getting crushed, CTXR just made a red to green move minutes ago and could be ready to continue its torrid stretch to start the year.
From a $.78 low on January 3rd, CTXR has been nothing short of magnificent as it has climbed to the $1.30+ range this week.
Could this be the start of something bigger?
With it already trading above its 50-Day Simple Moving Average (SMA), its 200-Day SMA, and its 13-Day Exponential Moving Average, there could be a ton of potential support for CTXR to run down previous highs.
And with a $10 analyst target, the potential upside is astounding from current levels.
Will CTXR run down its $10 target or its 52-week high this week? Probably not, but the potential upside needs to be noted from what could be considered undervalued levels.
Take a moment to read my initial report below and get CTXR on radar now.
Strap in. This could get wild. But first, a quick recap:
My first profile this week has now made a two day max move of approximately 59% from an open of $5.25 to Tuesday's $8.35 high.
That was followed with Wednesday's profile that surged approximately 27% intraday from its open to its high of day.
Now, I want to reintroduce another Nasdaq past champ to your immediate focus.
On April 19th, 2021, I brought this profile to your attention only to watch it run from an open that day of $1.99 to a high of $4.56 by June 22nd.
Overall, that approximate $2.00+ surge resulted in this breakout idea running approximately 129%.
And guess what? It's time to get it back on radar. Here's why...
Based on a significant analyst target providing over 650% potential upside, currently trading above 3 key lines of potential support, and the potential for FDA approval on the horizon, this past champ could be set for a breakthrough year in 2023.
For Thursday, January 19th, there is only one Nasdaq biopharma idea to have on your watch-list:
*Citius Pharmaceuticals, Inc. (CTXR)*
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies.
And right now, this profile has 4 potential catalysts to be fully aware of. They include:
No. 1 - A $10 Analyst Target Paints The Possibility For An Exceptionally Bright Future
No. 2 - Corporate Update Provides Glimpse Of How Big 2023 Could Be For CTXR
No. 3 - FDA Accepts Company's BLA For E7777, Target Action Date For PDUFA In September
No. 4 - Trading Above Key Support Lines Could Mean Big Things Ahead Near Term
But more on those in a second...
Citius Pharmaceuticals, Inc. (CTXR) Could Be A BioPharma Powerhouse Hiding In Plain Sight
Citius Pharmaceuticals is what’s called a “late-stage biopharmaceutical" company, where a highly-experienced management team purchases rights to the most promising new therapies and then either brings them to market or licenses rights to bigger pharma companies like Pfizer or Johnson & Johnson.
It should go without saying that “late-stage” development is the most difficult, most expensive part of the process for any new kind of treatment. Because even after years of in-vest-ment, research and development, some 2 out of 5 drugs still fail to secure final FDA approval.
But with a “Dream Team” of top industry insiders, Citius is turning the odds in their favor—with two treatments now in Phase 3.
Citius Pharmaceuticals quietly acquired the rights to the experimental compound “E-7777,” a direct improvement to a previously FDA-approved medication that directly attacks infected cancer cells inside the human body.
And this new cancer-fighting remedy could be mere months away from its own approval. If and when it hits the market, this new treatment could provide a whole new proven alternative to the harsh side effects of chemotherapy or aggressive radiation treatment.
Directly targeting and attacking infected cells, E-7777 could transform the potential $12.57Bn future market for Non-Hodgkin’s Lymphoma treatment.
The best part of this whole story? This is just one of several potentially game-changing new therapies in the company’s pipeline…